OncoPDCs

Excellamol has pioneered a new class of OncoPDCs in cancer therapeutics, consisting of cancer cell receptor-binding sequences, temperature-sensitive intrinsically disordered polypeptides, and highly potent antineoplastic agents. With high target selectivity and prolonged retention capability, OncoPDCs enable anticancer treatment to reach hard-to-access solid tumors locally, enhancing efficacy with minimal side effects.